1 October 2012 in Journal of Oral and Maxillofacial Surgery
10 November 2010 in Clinical Oral Implants Research
29 December 2024 in Journal of Oral Rehabilitation
Background: Botulinum toxin Type A (BTX‐A) is increasingly used in the management of myofascial pain; however, the evidence to support this treatment modality is still inconclusive.Objective: To evaluate the change in days with functional jaw pain after one session of BTX‐A or placebo injections into the masseter and temporalis muscles in subjects with jaw myalgia. The hypothesis was that BTX‐A is effective in reducing the number of days with functional jaw pain.Methods: This was a randomised, double‐blind, parallel group study in subjects with jaw myalgia. After randomisation, BTX‐A or placebo injections were made in the masseter and temporalis muscles. The number of days with jaw pain on function was evaluated after 2 months. Adverse events were registered.Results: Twenty‐three subjects were randomly assigned to BTX‐A and 22 to placebo. Between baseline and the 2‐month follow‐up, the number of days with jaw pain at function changed from a median (interquartile range) of 14 (4) to 10.5 (6) days in the BTX‐A group and from 14.0 (1.5) to 14 (5) in the saline group (p < 0.585). Adverse events were mild and transient and similar in the two groups.Conclusion: A single treatment of BTX‐A injections in the masseter and temporalis muscles was not effective in treating jaw myalgia. However, an adequately powered study might provide sufficient support for efficacy.
1 June 2017 in Clinical and Experimental Dental Research
To determine whether it is possible to vertically augment bone utilizing a block graft from compressed titanium granules mainly used previously for contained bone defects and to determine whether there exists a difference in osteoconductive properties between the white and the grey granules. In 11 rabbits, 4 titanium blocks were inserted on each rabbit's skull bone according to a randomized scheme. These blocks were made from standardized compressed titanium granules. Type A: PTG grey, small granules (Pourus Titanium Granules, Tigran, Malmö, Sweden); Type B: PTG grey, large granules; Type C: PTG white, small granules; Type D: PTG white large granules. After 12 weeks, the animals were sacrificed and specimens were collected for histology and μCT scanning. From both the μCT and histology, it can be said that bone formation was successfully achieved for all groups, and the granules maintained their volume. The histomorphometric BA (bone area) evaluation in the entire grafted area presented that there were no statistical differences between all groups tested. The lowest 1/4 BA in contact with the rabbit skull presented that groups A and C presented the highest mean BA, and group A presented significantly higher BA than that of group D (p = 0,049). No significant differences were noted between groups A, B and C. Within the limitation of this study, no differences were noted between small white or grey PTG blocks. The large granules presented less bone ingrowth area compared to the small granules and this trend was regardless of the different PTG types. The entire grafted area was not filled with new bone suggesting that bone migration occurred mostly from the existing cortical bone side suggesting contact osteogenesis.
1 February 2012 in European Urology Supplements